Sanofi-owned Genzyme said today it will build a new $80 million downstream processing facility for its Fabry disease treatment adjacent to its new Fabrazyme cell culture manufacturing site in Framingham, MA.
Sanofi-owned Genzyme said today it will build a new $80 million downstream processing facility for its Fabry disease treatment adjacent to its new Fabrazyme cell culture manufacturing site in Framingham, MA.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.